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Abstract
Neck of femur fractures predispose patients to venous thromboembolism (VTE). NICE has issued
guideline 46 to reduce this risk through the use of antithrombic agents. We audited our
department's VTE practise by reviewing the clinical notes of 123 consecutive patients with no
exclusions. We found our compliance to be a low 6%. We also found that patients were likely to
be given low molecular heparin (LMWH) only during their hospital stay. Reasons for the low
adherence were probably secondary to confusion caused by the multiple thromboprophylaxis
protocols used in our department. The correlation between duration of heparin administration and
length of hospital stay was due to logistical difficulty in administering VTE prophylaxis out of hospital
setting.
Background
In the absence of thromboprophylaxis the risk of develop-
ing a DVT post a primary total hip replacement is 50%
and 60% post a primary total knee replacement. The risk
of the DVT progressing to a PE is 1% and the risk of the PE
being fatal is 0.1%, a cumulative risk of fatality of 1 in 200
000 [1]. The mortality from a PE however increases mark-
edly to 12.9% [2] in the neck of femur fracture (NOF)
population not given prophylaxis. This increase being
attributed to an older patient population with multiple
co-morbidities, undergoing emergency surgery.
A meta analysis of randomised clinical trials has illus-
trated the progressive decrease in the incidence of DVT
post total hip and knee replacement with increasing
sophistication of anti-thrombic agent. For total hip
replacement without prophylaxis 50% will develop a
DVT, with aspirin 41.7%, adjusted dose warfarin 22.3%,
LMWH 14.8%, and the rate being lowest with fonda-
parinux at 4.7%. A similar trend is present following total
knee replacement. The incidence of DVT is 60% without
prophylaxis, 54.6% with aspirin, 37% with adjusted dose
warfarin, 35.1% with LMWH, and 12.5% with fonda-
parinux [3].
To reduce the risk of venous thromboembolism (VTE) in
inpatients undergoing surgery – NICE issued clinical
guideline 46 and The National Collaborating Centre for
Acute Care published by the Royal College of Surgeons of
England (RCSENG – NCC – AC) also published its guide-
line on VTE prevention in 2007. Both stated that patients
having surgery for hip fracture should be offered mechan-
ical prophylaxis and either LMWH or fondaparinux.
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4 weeks after hip fracture surgery.
In November 2007 we audited our Trauma department's
VTE prevention practice.
Objectives of audit
To measure our department's compliance with NICE
guideline CG046
To investigate the incidence of DVT/PE
To investigate the causes of non compliance
To offer conclusions and recommendations
Method
123 consecutive patients with no exclusions, who sus-
tained a neck of femur fracture (NOF) (intra- or extra-cap-
sular) between April and November 2007, and who were
treated by the Southport and Ormskirk Trauma and
Orthopaedic department were included in this audit.
Parameters measured
1. Whether low molecular weight heparin (LMWH) was
given for four weeks post surgery
2. The actual period of time for which LMWH was given
post surgery
3. Whether any of the patients developed a DVT or PE
prior to discharge
Results
Of the 123 patients included in the audit, 8 died in hospi-
tal. Only one of the deaths was due to CTPA proven pul-
monary embolism. Another patient developed
uncomplicated deep venous thrombosis. An overall rate
of VTE of 1.7%.
In the remaining 115 patients, LMWH was given for 4
weeks post surgery to 7(6%) patients only. There were
34(29%) cases where LMWH was not given for any period
of time. Reasons why LMWH was not given were as fol-
lows: 1 case of haematuria, 9 cases where the patients were
already on aspirin, 1 case where the patient was taking
clopidogrel, 2 patients were on warfarin, and 1 patient
refused. In 20 cases the reason for omission was not
stated.
It was interesting to note that where LMWH was given, the
period of administration corresponded to patient length
of stay in 85% of cases. The mean duration of LMWH
administration in NOF patients was 9.2 days. This implies
that most of the patients treated with LMWH were treated
whilst they were inpatients only.
Conclusion
The compliance in our Trauma department with NICE
guideline CG046 is low. It was implemented in 6% of
cases only.
Due to logistical reasons, LMWH tends to be given for the
duration of the patient's length of stay only. Methods to
facilitate the administration of LMWH for four weeks post
NOF surgery can include training the patient or relative in
subcutaneous injection of LMWH, or arranging district
nurse follow up. It also appears that in 10 (8.7%) of cases
aspirin and clopidogrel were wrongly assumed to be alter-
natives to LMWH.
Interviews with the nursing staff highlighted the high
number of differing thromboprophylaxis protocols cur-
rently in use in our Trauma department as a possible cause
of confusion and low compliance.
Recommendations and discussion
The Trauma and Orthopaedic department should adopt a
single thromboembolism prevention protocol and follow
the evidence based NICE and RCSENG – NCC – AC guide-
lines. Junior Doctors, Nurses and Pharmacy staff should
be educated in the content of the above guidelines and the
significance and incidence of VTE post NOF surgery.
A laminated copy should be provided in a prominent
place on the ward as an aide memoire. Following the
introduction of these recommendations, the data must be
re-audited to make sure that the compliance has
increased.
The importance of providing thromboprophylaxis for
four weeks post NOF surgery should be stressed. Follow-
ing TKR, THR or NOF surgery, there is a spike in hyperco-
agulability in the immediate post operative period with
gradual decay over time. However for THR and NOF
patients there is a bimodal distribution with a second
peak in VTE incidence at three to four weeks post opera-
tively [4].
It is interesting to read in the National Joint Registry 4th
annual report [5] that for primary hip replacement sur-
gery, mortality rates up to 1 year were compared between
patients with different types of thromboprophylaxis pre-
scribed at the time of surgery including those given no
prophylaxis. The evidence showed that there was no sta-
tistically significant difference in mortality between the
different types of prophylaxis prescribed including no
prophylaxis.Page 2 of 3
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It is however our opinion that we cannot extrapolate these
findings to include the NOF population until specific evi-
dence becomes available.
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